JD HEALTH Expands Partnership with Haleon

Written by Emily J. Thompson, Senior Investment Analyst

06618-2.92%

Source: aastocks

Updated: Jan 15 2026

0mins

Source: aastocks

Collaboration Announcement: JD Health has announced a deeper collaboration with Haleon to create a new health service ecosystem focused on holistic disease co-management and governance.
Expansion of Health Domains: The partnership will expand to cover over 15 health domains this year, including pediatric growth, respiratory health, and mental health.
Haleon's Background: Haleon, which was spun off from GSK in 2022, owns well-known consumer health brands such as Panadol, Sensodyne, and Centrum.
Market Performance: JD Health's stock has seen short selling of $120.48 million, with a ratio of 10.270%, while HSBC Research maintains a "Buy" rating with a target price of HKD 144.

06618

$64.85+Infinity%1D

Analyst Views on 06618

Wall Street analysts forecast 06618 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 06618 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Analyst Rating

0 Buy

0 Hold

0 Sell

Current: 66.800

Low

Averages

High

Current: 66.800

Low

Averages

High

Huatai Securities

Buy

maintain

2026-01-07

Reason

Huatai Securities

Price Target

AI Analysis

2026-01-07

maintain

Buy

Reason

The analyst rating from Huatai Securities for JD HEALTH is based on several key factors: 1. Revenue Growth: The report predicts a 22.7% year-over-year growth in 4Q25 revenue, driven by increased online penetration in the pharmaceutical category and the company's supply chain advantages. 2. Operating Profit: JD HEALTH is expected to achieve a non-IFRS operating profit of RMB260 million, indicating strong operational performance. 3. Seasonal Factors: The seasonal misalignment of the flu is anticipated to provide short-term support for revenue growth in the last quarter. 4. Long-term Projections: For the entire year of 2025, revenue is expected to increase by 25% year-over-year to RMB72.7 billion, with non-IFRS operating profit reaching RMB4.11 billion. 5. Revised Profit Forecasts: Huatai Securities has raised its non-IFRS net profit forecasts for JD HEALTH for 2025-2027 by significant percentages (11.6%/15.6%/22.4%), reflecting increased confidence in the company's financial performance. 6. Target Price Increase: The target price for JD HEALTH has been raised from HKD68.3 to HKD77.4, reinforcing a positive outlook. Overall, these factors contribute to Huatai Securities maintaining a "Buy" rating for JD HEALTH.

CICC

Outperform

maintain

$71.4

2026-01-06

Reason

CICC

Price Target

$71.4

2026-01-06

maintain

Outperform

Reason

CICC's analyst rating for JD HEALTH (06618.HK) is based on the expectation of nearly 25% year-over-year revenue growth and a stable, improving trend in operating profit margins, which reflects the company's strong competitive edge. Despite the typical peak investment season in 4Q25, CICC believes the company's performance will remain robust. They have maintained a target price of HKD 71.4 and an Outperform rating, indicating confidence in the company's future performance amidst sector challenges.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 06618

Unlock Now

Nomura

Buy

maintain

$80

2026-01-06

Reason

Nomura

Price Target

$80

2026-01-06

maintain

Buy

Reason

The analyst rating from Nomura for JD HEALTH is based on several positive expectations regarding the company's financial performance. They anticipate a 22% year-over-year increase in revenue for the fourth quarter of FY2025, driven by heightened demand for pharmaceuticals due to a surge in influenza cases. Additionally, they expect improvements in the operating profit margin and significant growth in both operating profit (72% YoY increase) and net profit (27% YoY increase). As a result of these optimistic projections, Nomura raised its earnings forecasts for FY2025 and FY2026 by 1%, maintaining a "Buy" rating and setting a target price of $80.

Morgan Stanley

Equalweight

maintain

$60

2025-11-19

Reason

Morgan Stanley

Price Target

$60

2025-11-19

maintain

Equalweight

Reason

Morgan Stanley raised its target price for JD HEALTH from $60 to $68.8 based on a discounted cash flow valuation, maintaining an Equalweight rating. The increase in target price is attributed to the company's growth in direct sales and service revenue, leading to a 1.4% rise in total revenue forecasts for 2025-2027. Additionally, the expansion of drug sales and a higher proportion of advertising revenue have contributed to an upward trend in the company's gross profit margin. Consequently, Morgan Stanley also elevated its recurring EPS estimations for the upcoming years by 9%, 13%, and 13%.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.